Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 07, 2021 4:01pm EDT
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress May 04, 2021 4:01pm EDT
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Apr 27, 2021 5:51pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Apr 02, 2021 4:35pm EDT
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Mar 14, 2021 4:00pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Mar 05, 2021 4:01pm EST
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress Mar 01, 2021 4:05pm EST
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Feb 18, 2021 4:01pm EST
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Feb 08, 2021 9:00am EST
